These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12039573)

  • 21. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and SAR studies for the inhibition of TNF-alpha production. Part 2. 2-[3-(Cyclopentyloxy)-4-methoxyphenyl]-substituted-1-isoindolinone derivatives.
    Park JS; Moon SC; Baik KU; Cho JY; Yoo ES; Byun YS; Park MH
    Arch Pharm Res; 2002 Apr; 25(2):137-42. PubMed ID: 12009025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Antimicrobial Evaluation of Novel Chiral 2-Amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Derivatives.
    Rossetti A; Bono N; Candiani G; Meneghetti F; Roda G; Sacchetti A
    Chem Biodivers; 2019 Jun; 16(6):e1900097. PubMed ID: 30942951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel potent imidazo[1,2-a]pyridine-N-Glycinyl-hydrazone inhibitors of TNF-α production: in vitro and in vivo studies.
    Lacerda RB; Sales NM; da Silva LL; Tesch R; Miranda AL; Barreiro EJ; Fernandes PD; Fraga CA
    PLoS One; 2014; 9(3):e91660. PubMed ID: 24632827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel cytokine production inhibitors produced by a basidiomycete, Marasmiellus sp.
    Ichikawa K; Hirai H; Ishiguro M; Kambara T; Kato Y; Kim YJ; Kojima Y; Matsunaga Y; Nishida H; Shiomi Y; Yoshikawa N; Kojima N
    J Antibiot (Tokyo); 2001 Sep; 54(9):703-9. PubMed ID: 11714225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and structure-activity relationship of cyclopentenone oximes as novel inhibitors of the production of tumor necrosis factor-α.
    Kim Y; Hong YD; Joo YH; Woo BY; Kim SY; Koh HJ; Park M; Byoun KH; Shin SS
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2807-10. PubMed ID: 24852119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors.
    Cheng JF; Chen M; Wallace D; Tith S; Arrhenius T; Kashiwagi H; Ono Y; Ishikawa A; Sato H; Kozono T; Sato H; Nadzan AM
    Bioorg Med Chem Lett; 2004 May; 14(10):2411-5. PubMed ID: 15109623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of 4,5,6,7-tetrahydrothieno[3,2-c]pyridines and comparison with their isosteric 1,2,3,4-tetrahydroisoquinolines as inhibitors of phenylethanolamine N-methyltransferase.
    Grunewald GL; Seim MR; Bhat SR; Wilson ME; Criscione KR
    Bioorg Med Chem; 2008 Jan; 16(1):542-59. PubMed ID: 18024134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noble 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-isoindolinone derivatives. part I: synthesis and SAR studies for the inhibition of TNF-alpha production.
    Park JS; Baik KU; Cho JY; Yoo ES; Byun YS; Park MH
    Arch Pharm Res; 2001 Oct; 24(5):367-70. PubMed ID: 11693533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
    Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
    Laufersweiler MJ; Brugel TA; Clark MP; Golebiowski A; Bookland RG; Laughlin SK; Sabat MP; Townes JA; VanRens JC; De B; Hsieh LC; Heitmeyer SA; Juergens K; Brown KK; Mekel MJ; Walter RL; Janusz MJ
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4267-72. PubMed ID: 15261284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 6-Tosyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide analogues: synthesis, characterization, MO calculation, and antibacterial activity.
    Doshi H; Thakkar S; Khirsariya P; Thakur MC; Ray A
    Appl Biochem Biotechnol; 2015 Feb; 175(3):1700-9. PubMed ID: 25422060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.
    Green N; Hu Y; Janz K; Li HQ; Kaila N; Guler S; Thomason J; Joseph-McCarthy D; Tam SY; Hotchandani R; Wu J; Huang A; Wang Q; Leung L; Pelker J; Marusic S; Hsu S; Telliez JB; Hall JP; Cuozzo JW; Lin LL
    J Med Chem; 2007 Sep; 50(19):4728-45. PubMed ID: 17715908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The relationship between reactive oxygen species-dependent activation of p38 MAPK and the expression of tumor necrosis factor-α in cultured cardiomyocytes].
    Shang FJ; Wang JP; Zheng QS; Liu XT; Xue YS; Li J; Zhao LY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jan; 27(1):7-10. PubMed ID: 21208554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.
    Kroth H; Sreenivasachary N; Hamel A; Benderitter P; Varisco Y; Giriens V; Paganetti P; Froestl W; Pfeifer A; Muhs A
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3330-3335. PubMed ID: 27256911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-alpha production.
    Park JS; Balk KU; Son HJ; Lee JH; Lee SJ; Cho JY; Park J; Yoo ES; Byun YS; Park MH
    Arch Pharm Res; 2000 Aug; 23(4):332-7. PubMed ID: 10976579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
    Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
    J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway.
    Yoshinari D; Takeyoshi I; Koibuchi Y; Matsumoto K; Kawashima Y; Koyama T; Ohwada S; Morishita Y
    Crit Care Med; 2001 Mar; 29(3):628-34. PubMed ID: 11373433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.